Search Results

There are 1525 results for: content related to: HCV Therapeutics: New Agents

  1. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28228

  2. You have free access to this content
    Poster Session II (Abstracts 730 – 1194)

    Hepatology

    Volume 64, Issue S1, October 2016, Pages: 361–601,

    Version of Record online : 1 OCT 2016, DOI: 10.1002/hep.28798

  3. You have free access to this content
    Poster Session 2: Hepatitis C: Approved Therapeutic Agents

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 659A–709A,

    Version of Record online : 1 OCT 2014, DOI: 10.1002/hep.27516

  4. You have free access to this content
    Poster Session IV (Abstracts 1638 – 2112)

    Hepatology

    Volume 64, Issue S1, October 2016, Pages: 811–1050,

    Version of Record online : 1 OCT 2016, DOI: 10.1002/hep.28800

  5. You have free access to this content
    Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus

    Journal of Pharmacy and Pharmacology

    Volume 66, Issue 12, December 2014, Pages: 1653–1666, Bryant B. Summers, Joshua W. F. Beavers and Olga M. Klibanov

    Version of Record online : 31 AUG 2014, DOI: 10.1111/jphp.12294

  6. You have free access to this content
    JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

    Hepatology Research

    Volume 46, Issue 2, February 2016, Pages: 129–165, Yasuhiro Asahina, Namiki Izumi, Kumada Hiromitsu, Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu and Hiroshi Yotsuyanagi

    Version of Record online : 15 FEB 2016, DOI: 10.1111/hepr.12645

  7. Development of sofosbuvir for the treatment of hepatitis C virus infection

    Annals of the New York Academy of Sciences

    Volume 1358, Issue 1, November 2015, Pages: 56–67, Eric Lawitz, Ira M. Jacobson, David R. Nelson, Stefan Zeuzem, Mark S. Sulkowski, Rafael Esteban, Diana Brainard, John McNally, William T. Symonds, John G. McHutchison, Douglas Dieterich and Edward Gane

    Version of Record online : 31 JUL 2015, DOI: 10.1111/nyas.12832

  8. You have free access to this content
    Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions

    Clinical Pharmacology in Drug Development

    Volume 6, Issue 2, March/April 2017, Pages: 147–163, Justin Chan and Raymond T. Chung

    Version of Record online : 6 MAR 2017, DOI: 10.1002/cpdd.338

  9. You have free access to this content
    Poster Sessions

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 93A–207A,

    Version of Record online : 1 OCT 2015, DOI: 10.1002/hep.28162

  10. Ledipasvir–Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 36, Issue 5, May 2016, Pages: 562–574, Christopher M. Jensen and Lisa M. Holle

    Version of Record online : 12 MAY 2016, DOI: 10.1002/phar.1748

  11. You have free access to this content
    Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

    Hepatology

    Volume 62, Issue 3, September 2015, Pages: 932–954, AASLD/IDSA HCV Guidance Panel

    Version of Record online : 4 AUG 2015, DOI: 10.1002/hep.27950

  12. You have free access to this content
    Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 5, March 2014, Pages: 478–487, R. S. Koff

    Version of Record online : 6 JAN 2014, DOI: 10.1111/apt.12601

    Corrected by:

    Corrigenda: Corrigenda

    Vol. 39, Issue 8, 904, Version of Record online: 17 MAR 2014

  13. You have free access to this content
    Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 6, September 2014, Pages: 657–675, S. Saab, S. C. Gordon, H. Park, M. Sulkowski, A. Ahmed and Z. Younossi

    Version of Record online : 28 JUL 2014, DOI: 10.1111/apt.12871

  14. You have free access to this content
    All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database

    Alimentary Pharmacology & Therapeutics

    Volume 45, Issue 1, January 2017, Pages: 115–126, K. R. Reddy, J. K. Lim, A. Kuo, A. M. Di Bisceglie, J. S. Galati, G. Morelli, G. T. Everson, P. Y. Kwo, R. S. Brown Jr., M. S. Sulkowski, L. Akuschevich, A. S. Lok, P. J. Pockros, M. Vainorius, N. A. Terrault, D. R. Nelson, M. W. Fried, M. P. Manns and for the HCV-TARGET Study Group

    Version of Record online : 28 OCT 2016, DOI: 10.1111/apt.13823

  15. You have free access to this content
    Poster Session 4: Hepatitis C: New Agents (Not Approved)

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 1128A–1161A,

    Version of Record online : 1 OCT 2014, DOI: 10.1002/hep.27533

  16. You have free access to this content
    Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 12, June 2014, Pages: 1363–1375, M. H. Miller, K. Agarwal, A. Austin, A. Brown, S. T. Barclay, P. Dundas, G. M. Dusheiko, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, C. Millson, S. D. Ryder, J. Tait, A. Ustianowski and J. F. Dillon

    Version of Record online : 22 APR 2014, DOI: 10.1111/apt.12764

  17. You have full text access to this OnlineOpen article
    Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 37, Issue 6, June 2017, Pages: 735–747, Michelle T. Martin and Paulina Deming

    Version of Record online : 12 MAY 2017, DOI: 10.1002/phar.1933

  18. You have free access to this content
    Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis

    Alimentary Pharmacology & Therapeutics

    Volume 43, Issue 12, June 2016, Pages: 1276–1292, A. Majumdar, M. T. Kitson and S. K. Roberts

    Version of Record online : 18 APR 2016, DOI: 10.1111/apt.13633

  19. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR)

    Journal of Viral Hepatitis

    Volume 20, Issue 10, October 2013, Pages: 699–707, E. J. Lawitz, M. Rodriguez-Torres, J. Denning, A. Mathias, H. Mo, B. Gao, M. T. Cornpropst, M. M. Berrey and W. T. Symonds

    Version of Record online : 31 MAR 2013, DOI: 10.1111/jvh.12091

  20. You have free access to this content
    Plenary and Parallel Sessions (Abstracts 1–258)

    Hepatology

    Volume 64, Issue S1, October 2016, Pages: 1–136,

    Version of Record online : 1 OCT 2016, DOI: 10.1002/hep.28796